Showing posts with label Insulin. Show all posts
Showing posts with label Insulin. Show all posts

Wednesday, August 15, 2012

Amylin announces results from SYMLIN clinical studies on type 2 or 1 diabetes

Amylin announces results from SYMLIN clinical studies on type 2 or 1 diabetes: Amylin Pharmaceuticals, Inc. today announced results from new analyses of previously completed clinical studies demonstrating that patients with type 2 or type 1 diabetes achieved a greater proportion of blood glucose measurements in the normal range when SYMLIN (pramlintide acetate, see structure) injection treatment was used along with insulin...

Ref :

Friday, June 3, 2011

Lyxumia®, as an add-on to basal Insulin, shows significant positive phase III results

Sanofi  announced today that new results from a Phase III study showed that the investigational product Lyxumia® (lixisenatide see structure above), when used as an add-on therapy to basal insulin (in association with or without metformin), achieved its primary efficacy endpoint of significantly reducing HbA1c versus placebo for patientswith type 2 diabetes without significantly increasing their risk of hypoglycemia...


Friday, October 2, 2009

New markers for early detection Of type 1 diabetes !

As per the claim by the lead researchers Prof. Dr. Anette Ziegler and Dr. Peter Achenbach, genetic factors play a significant role in the development of type 1 diabetes. The scientists were able to show that specific variants of the zinc transporter gene SLC30A8 influence the risk for diabetes. The body needs this gene in order to produce ZnT8. This protein influences the zinc transport into the beta cells and plays a crucial role in their maturation and thus also in insulin secretion.

Beta cells of the islets of Langerhans in the pancreas secrete the vitally important insulin. Already prior to the onset of type 1 diabetes the body’s own immune system destroys the beta cells. If this destruction exceeds a certain threshold, the disease becomes manifest: The insulin deficiency leads to various metabolic disturbances, including elevated blood glucose levels. Autoantibodies to ZnT8 in combination with a specific variant of the zinc transporter gene were associated with an elevated diabetes risk. The researchers claims that "Autoantibodies to ZnT8 are an additional important marker for the progression of diabetes – especially in children who are already developing islet autoantibodies. Hence larger the number of different kinds of autoantibodies, the higher the risk for diabetes, and the younger the child with autoantibodies, the earlier disease onset will be. Its a good achievement. Congrats....

Ref :